Tango Therapeutics, Inc.
TNGX
株式のランク
#4535
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
株価
$27.18
最終同期: 2026-07-31
時価総額
$3.38B
変化（1日）
-1.41%
変化（1年）
197.05%
国
US
取引 Tango Therapeutics, Inc. (TNGX)
カテゴリー
Healthcare
Tango Therapeutics, Inc.（TNGX）のEPS
June 2026 時点のEPS TTM: $-0.85
Tango Therapeutics, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-0.85です。2023年末には、EPSは$-1.08で、2022年のEPS$-1.23と減少でした。
Tango Therapeutics, Inc.のEPS履歴（2019から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-0.85 | -28.57% |
| 2024 | $-1.19 | 10.19% |
| 2023 | $-1.08 | -12.20% |
| 2022 | $-1.23 | 30.85% |
| 2021 | $-0.94 | -41.98% |
| 2020 | $-1.62 | 3.18% |
| 2019 | $-1.57 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -2,137.65% |
US
|
|
| $-7.98 | 838.82% |
US
|
|
| $-5.29 | 522.35% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,363.53% |
NL
|
